Home > Cardiology > ACC 2022 > Interventional and Structural Cardiology > Head-to-head: post-TAVR edoxaban not better than DAPT

Head-to-head: post-TAVR edoxaban not better than DAPT

Presented By
Prof. Duk-Woo Park, Asan Medical Center, Korea
Conference
ACC 2022
Trial
Phase 4, ADAPT-TAVR
Results from the underpowered ADAPT-TAVR study showed that patients who had received a successful transcatheter aortic valve replacement (TAVR) did not have a significantly reduced incidence of leaflet thrombosis with edoxaban than with dual antiplatelet therapy (DAPT), despite a numerical trend. Effects on cerebral thromboembolism, neurological function, and bleeding were also similar between the arms. The findings of ADAPT-TAVR (NCT03284827) were presented by Prof. Duk-Woo Park (Asan Medical Center, Korea) and simultaneously published in Circulation [1,2]. ADAPT-TAVR randomised patients who had just received a TAVR (n=229; average age 80 years; 58% women) to either receive 6 months of edoxaban or 6 months of DAPT in this head-to-head study. The primary endpoint was the incidence of subclinical leaflet thrombosis (SLT) in the 6 months aft...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on